The patient with the MYD88 L265P mutation (ECD5) developed CNS involvement and died of lymphoma 42 months after diagnosis, despite second-line treatment with radiotherapy and immune-polychemotherapy (R-CHOP). This evidence concerns the gene MYD88 and lymphoma.